Nanosystems for simultaneous imaging and drug delivery to T cells

AAPS Journal

Volumn 9, Issue 2, 2007, Pages

  Fahmy, Tarek M ^a   Fong, Peter M ^a   Park, Jason ^a   Constable, Todd ^a,b   Saltzman, W Mark ^a  

^a Yale University   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug delivery; Nanoparticles; Noninvasive imaging; T cells

Indexed keywords

ALBUMIN; BOVINE SERUM ALBUMIN; CONTRAST MEDIUM; DENDRIMER; DOXORUBICIN; FLUOROCHROME; FLUORODEOXYGLUCOSE F 18; FOLIC ACID; GADOLINIUM; GADOLINIUM PENTETATE; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; IMMUNOSUPPRESSIVE AGENT; INDIUM 111; IRON OXIDE; LIGAND; LIPOSOME; MACROGOL; MANGANESE CHLORIDE; NANOPARTICLE; POLYAMIDOAMINE; POLYGLACTIN; POLYGLYCOLIC ACID; POLYLACTIC ACID; STREPTAVIDIN; SUPERPARAMAGNETIC IRON OXIDE; T LYMPHOCYTE ANTIGEN; T LYMPHOCYTE RECEPTOR; TECHNETIUM 99M; TRANSACTIVATOR PROTEIN; UNINDEXED DRUG;

ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; BIODEGRADATION; BIOLUMINESCENCE; COLORIMETRY; DRUG DELIVERY SYSTEM; ENCAPSULATION; FLUORESCENCE ANALYSIS; HUMAN; ILLUMINATION; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LYMPHOCYTE MIGRATION; MACROMOLECULE; MAJOR HISTOCOMPATIBILITY COMPLEX; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROTEIN TARGETING; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; T LYMPHOCYTE;

EID: 34250685362     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/aapsj0902019     Document Type: Review

References (89)

1. Steinman L. Autoimmune-disease. Sci Am. 1993;269:106.
2. Hasler P. Biological therapies directed against cells in autoimmune disease. Springer Semin Immunopathol. 2006;27:443-456.
3. Ogg GS. T-cell immunotherapy of allergic disease: the role of CD8+ T cells. Curr Opin Allergy Clin Immunol. 2003;3:475-479.
4. Westermann J, Bode U. Distribution of activated T cells migrating through the body: a matter of life and death. Immunol Today. 1999;20:302-306.
5. Westermann J, Ehlers EM, Exton MS, Kaiser M, Bode U. Migration of naive, effector and memory T cells: implications for the regulation of immune responses. Immunol Rev. 2001;184:20-37.
6. Westermann J, Engelhardt B, Hoffmann JC. Migration of T cells in vivo: molecular mechanisms and clinical implications. Ann Intern Med. 2001;135:279-295.
7. Germain RN, Miller MJ, Dustin ML, Nussenzweig MC. Dynamic imaging of the immune system: progress, pitfalls and promise. Nat Rev Immunol. 2006;6:497-507.
8. Bradley LM. Migration and T-lymphocyte effector function. Curr Opin Immunol. 2003; 15:343-348.
9. Hennecke J, Wiley DC. T cell receptor-MHC interactions up close. Cell 2001;104:1-4.
10. Corr M, Slanetz AE, Boyd LF, et al. T cell receptor-MHC class I peptide interactions: affinity, kinetics, and specificity. Science. 1994;265:946-949.
11. Sykulev Y, Brumnark A, Jackson M, Cohen RJ, Peterson PA, Eisen HN. Kinetics and affinity of reactions between an antigen-specific T cell receptor and peptide-MHC complexes. Immunity 1994; 1:15-22.
12. Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996;274:94-96.
13. Constantin CM, Bonney EE, Altman JD, Strickland OL. Major histocompatibility complex (MHC) tetramer technology: an evaluation. Biol Res Nurs. 2002;4:115-127.
14. Howard MC, Spack EG, Choudhury K, Greten TF, Schneck JP. MHC-based diagnostics and therapeutics - clinical applications for disease-linked genes. Immunol Today. 1999;20:161-165.
15. Klenerman P, Cerundolo V, Dunbar PR. Tracking T cells with tetramers: new tales from new tools. Nat Rev Immunol. 2002;2:263-272.
16. Schwartz RH. T cell anergy. Annu Rev Immunol. 2003;21:305-334.
17. Casares S, Stan AC, Bona CA, Brumeanu TD. Antigen-specific downregulation of T cells by doxorubicin delivered through a recombinant MHC II-peptide chimera. Nat Biotechnol. 2001;19:142-147.
18. Cahalan MD, Parker I. Imaging the choreography of lymphocyte trafficking and the immune response. Curr Opin Immunol. 2006;18:476-482.
19. Iparraguirre A, Weninger W. Visualizing T cell migration in vivo. Int Arch Allergy Immunol. 2003;132:277-293.
20. Reinhardt RL, Jenkins MK. Whole-body analysis of T cell responses. Curr Opin Immunol. 2003; 15:366-371.
21. Reinhardt RL, Khoruts A, Merica R, Zell T, Jenkins MK. Visualizing the generation of memory CD4 T cells in the whole body. Nature. 2001;410:101-105.
22. Cahalan MD, Parker I, Wei SH, Miller MJ. 2-photon tissue imaging: seeing the immune system in a fresh light. Nat Rev Immunol. 2002;2:872-880.
23. Wei SH, Miller MJ, Cahalan MD, Parker I. Two-photon imaging in intact lymphoid tissue. Adv Exp Med Biol. 2002;512:203-208.
24. Miller MJ, Wei SH, Cahalan MD, Parker I. Autonomous T cell trafficking examined in vivo with intravital two-photon microscopy. Proc Natl Acad Sci USA. 2003; 100:2604-2609.
25. Osman S, Danpure HJ. The use of 2-[18F]fluoro-2-deoxy-D-glucose as a potential in vitro agent for labelling human granulocytes for clinical studies by positron emission tomography. Int J Rad Appl Instrum B. 1992; 19:183-190.
26. Roddie ME, Peters AM, Danpure HJ, et al. Inflammation: imaging with Tc-99m HMPAO-labeled leukocytes. Radiology. 1988;166:767-772.
27. Edinger M, Cao YA, Hornig YS, et al. Advancing animal models of neoplasia through in vivo bioluminescence imaging. Eur J Cancer. 2002;38:2128-2136.
28. Mandl S, Schimmelpfennig C, Edinger M, Negrin RS, Contag CH. Understanding immune cell trafficking patterns via in vivo bioluminescence imaging. J Cell Biochem. 2002;87:239-248.
29. Costa GL, Sandora MR, Nakajima A, et al. Adoptive immuno-therapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p4O subunit. J Immunol. 2001;167:2379-2387.
30. Nakajima A, Seroogy CM, Sandora MR, et al. Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis. J Clin Invest. 2001;107:1293-1301.
31. Herschman HR. Micro-PET imaging and small animal models of disease. Curr Opin Immunol. 2003; 15:378-384.
32. Sosnovik D, Weissleder R. Magnetic resonance and fluorescence based molecular imaging technologies. Prog Drug Res. 2005;62:83-115.
33. Levchenko TS, Rammohan R, Volodina N, Torchilin VP. Tat peptide-mediated intracellular delivery of liposomes. Methods Enzymol. 2003;372:339-349.
34. Wunderbaldinger P, Josephson L, Weissleder R. Tat peptide directs enhanced clearance and hepatic permeability of magnetic nanoparticles. Bioconjug Chem. 2002;13:264-268.
35. Smimov P, Lavergne E, Gazeau F, et al. In vivo cellular imaging of lymphocyte trafficking by MRI: a tumor model approach to cell-based anticancer therapy. Magn Reson Med. 2006;56:498-508.
36. Matuszewski L, Persigehl T, Wall A, et al. Cell tagging with clinically approved iron oxides: feasibility and effect of lipofection, particle size, and surface coating on labeling efficiency. Radiology. 2005;235:155-161.
37. Gregoriadis G, Neerunjun T. Homing of liposomes to target cells. Biochem Biophys Res Commun. 1975;65:537-544.
38. Gregoriadis G. Targeting of drugs: implications in medicine. Lancet. 1981;318:241-246.
39. Gregoriadis G. The carrier potential of liposomes in biology and medicine. N Engl J Med. 1976;704:110.
40. Gregoriadis G. Drug entrapment in liposomes. FEBS Lett. 1973;36:292-296.
41. Laverman P, Boerman OC, Oyen WJ, Dams ET, Storm G, Corstens FH. Liposomes for scintigraphic detection of infection and inflammation. Adv Drug Deliv Rev. 1999;37:225-235.
42. Mulder WJ, Strijkers GJ, van Tilborg GA, Griffioen AW, Nicolay K. Lipid-based nanoparticles for contrast-enhanced MR1 and molecular imaging. NMR Biomed. 2006; 19:142-164.
43. Torchilin VP. Liposomes as delivery agents for medical imaging. Mol Med Today. 1996;2:242-249.
44. Waterhouse DN, Madden TD, Cullis PR, Bally MB, Mayer LD, Webb MS. Preparation, characterization, and biological analysis of liposomal formulations of vincristine. Methods Enzymol. 2005;391:40-57.
45. Haran G, Cohen R, Bar LY, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta. 1993; 1151:201-215.
46. Sapra P, Allen TM. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res. 2003;42:439-462.
47. Allen TM, Sapra P, Moase E, Moreira J, Iden D. Adventures in targeting. J Liposome Res. 2002;12:5-12.
48. Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res. 2000;6:1949-1957.
49. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4:145-160.
50. Boerman OC, Laverman P, Oyen WJ, Corstens FH, Storm G. Radiolabeled liposomes for scintigraphic imaging. Prog Lipid Res. 2000;39:461475.
51. Andreopoulos D, Kasi LP, Asimacopoulos PJ, et al. Selective in vitro labeling of white blood cells using 99mTc-labeled liposomes. Nucl Med Biol. 2002;29:185-190.
52. Harrington KJ, Mohammadtaghi S, Uster PS, et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res. 2001;7:243-254.
53. Proffitt RT, Williams LE, Presant CA, et al. Tumor-imaging potential of liposomes loaded with In-111-NTA: biodistribution in mice. J Nucl Med. 1983;24:45-51.
54. Bulte JW, Ma LD, Magin RL, et al. Selective MR imaging of labeled human peripheral blood mononuclear cells by liposome mediated incorporation of dextran-magnetite particles. Magn Reson Med. 1993;29:32-37.
55. Martina MS, Fortin JP, Menager C, et al. Generation of superparamagnetic liposomes revealed as highly efficient MRI contrast agents for in vivo imaging. J Am Chem Soc. 2005;127:10676-10685.
56. De Cuyper M, Joniau M. Magnetoliposomes. Formation and structural characterization. Eur Biophys J. 1988;15:311-315.
57. Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci. 2002;6:319-327. '
58. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70:1-20.
59. Wiener EC, Brechbiel MW, Brothers H, et al. Dendrimer-based metal chelates: a new class of magnetic resonance imaging contrast agents. Magn Reson Med. 1994;31:1-8.
60. Jansen JFGA, De Brabander-van den Berg EMM, Meijer EW. Encapsulation of guest molecules into a dendritic box. Science. 1994;266:1226-1229.
61. D'Emanuele A, Attwood D. Dendrimer-drug interactions. Adv Drug Deliv Rev. 2005;57:2147-2162.
62. Esfand R, Tomalia DA. Poly(amidoamine) (PAMAM) dendrimers from biomimicry to drug delivery and biomedical applications. Drug Discov Today. 200 1;6:427-436.
63. Kobayashi H, Jr, Kawamoto S, Jr, Jo SK, Jr, Bryant HL, Jr, Brechbiel MW, Star RA. Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores. Bioconjug Chem. 2003;14:388-394.
64. Klajnert B, Bryszewska M. Dendrimers: properties and applications. Acta Biochim Pol. 2001;48:199-208.
65. Liu MJ, Kono K, Frechet JMJ. Water-soluble dendrimer-poly(ethylene glycol) starlike conjugates as potential drug carriers. J Polym Sci A. 2000;37:3492-3503.
66. Kojima C, Kono K, Maruyama K, Takagishi T. Synthesis of polyamidoaminedendrimers having poly(ethyleneglycol) grafts and their ability to encapsulate anticaner drugs. Bioconjugate Chem. 2000;11:910-917.
67. Jansen JFGA, Meijer EW, de Brabander-van den Berg EMM. The dendritic box: shape-selective liberation of encapsulated guests. J Am Chem Soc. 1995;117:4417-4418.
68. Luo D, Haverstick K, Belcheva N, Han E, Saltzman WM. Poly(ethylene glycol)-conjugated PAMAM dendrimer for biocompatible, high-efficiency DNA delivery. Macromolecules. 2002;35:3456-3462.
69. Dennig J, Duncan E. Gene transfer into eukaryotic cells using activated polyamidoamine dendrimers. J Biotechnol. 2002;90:339-347.
70. Yoo HS, Lee KH, Oh JE, Park TG. In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. J Control Release. 2000;68:419-431.
71. Kobayashi H, Wu C, Kim MY, Paik CH, Carrasquillo JA, Brechbiel MW. Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody. Bioconjug Chem. 1999;10:103-111.
72. Talanov VS, Regino CA, Kobayashi H, Bernardo M, Choyke PL, Brechbiel MW. Dendrimer-based nanoprobe for dual modality magnetic resonance and fluorescence imaging. Nano Lett. 2006;6:1459-1463.
73. Venditto VJ, Regino CA, Brechbiel MW. PAMAM dendrimer based macromolecules as improved contrast agents. Mol Pharm. 2005;2:302-311.
74. Pan D, Turner JL, Wooley KL. Folic acid-conjugated nanostructured materials designed for cancer cell targeting. Chem Commun (Camb). 2003; 19:2400-2401.
75. Daly T, Royal RE, Kershaw MH, et al. Recognition of human colon cancer by T cells transduced with a chimeric receptor gene. Cancer Gene Ther. 2000;7:284-291.
76. Sakharov DV, Jie AF, Filippov DV, Bekkers ME, van Boom JH, Rijken DC. Binding and retention of polycationic peptides and dendrimers in the vascular wall. FEBS Lett. 2003;537,:6-10.
77. Wiwattanapatapee R, Lomlim L, Saramunee K. Dendrimers conjugates for colonic delivery of 5-aminosalicylic acid. J Control Release. 2003;88:1-9.
78. Fahmy T, Schneck J, Saltzman W. A nanoscopic multivalent antigen-presenting carrier for sensitive detection and drug delivery to T cells. Nanomedicine. In press.
79. Belcheva N, Baldwin SP, Saltzman WM. Synthesis and characterization of polymer-(multi)-peptide conjugates for control of specific cell aggregation. J Biomater Sci Polym Ed. 1998;9:207-226.
80. Belcheva N, Woodrow-Mumford K, Mahoney MJ, Saltzman WM. Synthesis and biological activity of polyethylene glycol-mouse nerve growth factor conjugate. Bioconjug Chem. 1999;10:932-937.
81. Katre NV. The conjugation of proteins with polyethylene glycol and other polymers altering properties of proteins to enhance their therapeutic potential. Adv Drug Deltv Rev. 1993;10:91-114.
82. Kobayashi H, Brechbiel MW. Dendrimer-based nanosized MRI contrast agents. Curr Pharm Biotechnol. 2004;5:539-549.
83. Kobayashi H, Brechbiel MW. Nano-sized MRI contrast agents with dendrimer cores. Adv Drug Deliv Rev. 2005;57:2271-2286.
84. Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 1997;28:5-24.
85. Langer R, Folkman J. Polymers for the sustained release of proteins and other macromolecules. Nature. 1976;263:797-800.
86. Visscher GE, Robison RL, Maulding HV, Fong JW, Pearson JE, Argentieri GJ. Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-glycolide) microcapsules. J Biomed Mater Res. 1985;19:349-365.
87. Emerich DF, Snodgrass P, Lafreniere D, et al. Sustained release chemotherapeutic microspheres provide superior efficacy over systemic therapy and local bolus infusions. Pharm Res. 2002;19:1052-1060.
88. Hu YP, Jarillon S, Dubernet C, Couvreur P, Robert J. On the mechanism of action of doxorubicin encapsulation in nanospheres for the reversal of multidrug resistance. Cancer Chemother Pharmacol. 1996;37:556-560.
89. Chen HH, Le Visage C, Qiu B. et al. MR imaging of biodegradable polymeric microparticles: a potential method of monitoring local drug delivery. Magn Reson Med. 2005;53:614-620.